The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma

BackgroundDifferentiating true glioblastoma multiforme (GBM) from pseudoprogression (PsP) remains a challenge with current standard magnetic resonance imaging (MRI). The objective of this study was to explore whether patients' absolute lymphocyte count (ALC) levels can be utilized to predict true tumor progression and PsP.MethodsPatients were considered eligible for the study if they had 1) GBM diagnosis, 2) a series of blood cell counts and clinical follow-ups, and 3) tumor progression documented by both MRI and pathology. Data analysis results include descriptive statistics, median (IQR) for continuous variables and count (%) for categorical variables, p values from Wilcoxon rank sum test or Fisher's exact test for comparison, respectively, and Kaplan-Meier analysis for overall survival (OS). OS was defined as the time from patients' second surgery to their time of death or last follow up if patients were still alive.Results78 patients were included in this study. The median age was 56years. Median ALC dropped 34.5% from baseline 1400 cells/mm(3) to 917 cells/mm(3) after completion of radiation therapy (RT) and temozolomide (TMZ). All study patients had undergone surgical biopsy upon MRI-documented progression. 37 had true tumor progression (47.44%) and 41 had pseudoprogression (52.56%). ALC before RT/TMZ, post RT/TMZ and at the time of MRI-documented progression did not show significant difference between patients with true progression and PsP. Although not statistically significant, this study found that patients with true progression had worse OS compared to those with PsP (Hazard Ratio [HR] 1.44, 95% CI 0.86-2.43, P=0.178). This study also found that patients with high ALC (dichotomized by median) post-radiation had longer OS.ConclusionOur results indicate that ALC level in GBM patients before or after treatment does not have predictive value for true disease progression or pseudoprogression. Patients with true progression had worse OS compared to those who had pseudoprogression. A larger sample size that includes CD4 cell counts may be needed to evaluate the PsP predictive value of peripheral blood biomarkers.

Automated summary

This study suggests that ALC levels before or after treatment do not predict true disease progression or pseudoprogression in GBM patients. Patients with true progression had worse overall survival compared to those with pseudoprogression. A larger sample size including CD4 cell counts may be needed to evaluate the predictive value of peripheral blood biomarkers for pseudoprogression.